Effects of multistrain probiotic supplementation on systemic inflammation, nutritional status, functional capacity and quality of life in maintenance hemodialysis: an open-label randomized controlled trial

Maulik Patel; Gaurang Patel; Girish Chaudhary; Akash Dholakia

doi:10.18203/2349-3933.ijam20263721

Authors

Maulik Patel Department of Nephrology, Shankus hospital, Mehsana, Gujarat, India https://orcid.org/0009-0008-4941-3478
Gaurang Patel Department of Cardiology, Shankus hospital, Mehsana, Gujarat, India
Girish Chaudhary Department of Pulmonary Medicine, Shankus hospital, Mehsana, Gujarat, India
Akash Dholakia Department of Nephrology, Shankus hospital, Mehsana, Gujarat, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20263721

Keywords:

Gut kidney axis, Hemodialysis, Inflammation, Malnutrition, Probiotics, Quality of life

Abstract

Background: Persistent inflammation, protein-energy wasting, impaired physical function and reduced health-related quality of life are common among patients receiving maintenance hemodialysis. Intestinal dysbiosis and increased exposure to gut-derived inflammatory mediators may contribute to these abnormalities. This study evaluated the effects of multistrain probiotic supplementation on inflammatory, nutritional, functional, clinical, safety and patient-reported outcomes in adults undergoing maintenance hemodialysis.

Methods: This prospective, single-center, open-label, parallel-group randomized controlled trial enrolled 60 adults receiving maintenance hemodialysis. Participants were randomized in a 1:1 ratio to receive a daily four-strain probiotic plus standard hemodialysis care or standard care alone for 6 months. The primary outcome was the systemic immune-inflammation index (SII) at month 6. Secondary outcomes included the neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), red cell distribution width (RDW), serum albumin, malnutrition-inflammation score (MIS), handgrip strength, kidney disease quality of life-36 (KDQOL-36), hospitalization, adherence, nutritional response, all-cause mortality and adverse events.

Results: At month 6, the probiotic group had significantly lower SII (p=0.013), NLR (p=0.024), CRP (p=0.045), RDW (P=0.010) and MIS (p=0.018) and significantly higher serum albumin (p=0.005), handgrip strength (p=0.027) and KDQOL-36 scores (p=0.031) than the control group. No statistically significant between-group differences were observed in hospitalization, adherence, predefined nutritional response, all-cause mortality, gastrointestinal adverse events or serious intervention-related adverse events.

Conclusions: Six months of multistrain probiotic supplementation was associated with favorable changes in systemic inflammation, nutritional status, muscle strength and kidney disease-specific quality of life among adults receiving maintenance hemodialysis. No detectable benefit was observed for hospitalization, mortality or adverse-event frequency. These findings should be interpreted cautiously because of the modest sample size and open-label, single-center design.

References

Cockwell P, Fisher LA. The global burden of chronic kidney disease. Lancet. 2020;395(10):662-4.

Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences and therapy. Semin Dial. 2002;15(5):329-37.

Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73(4):391-8.

Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42(5):864-81.

Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83(2):308-15.

Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39(3):230-7.

Vaziri ND, Yuan J, Norris K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol. 2013;37(1):1-6.

Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, et al. Colonic contribution to uremic solutes. J Am Soc Nephrol. 2011;22(9):1769-76.

Ramezani A, Raj DS. The gut microbiome, kidney disease and targeted interventions. J Am Soc Nephrol. 2014;25(4):657-70.

Vanholder R, Glorieux G, De Smet R, Lameire N. European Uremic Toxin Work Group. New insights in uremic toxins. Kidney Int Suppl. 2003;(84):6-10.

Chen C, Wang J, Li J, Zhang W, Ou S. Probiotics, prebiotics and synbiotics for patients on dialysis: a systematic review and meta-analysis of randomized controlled trials. J Ren Nutr. 2023;33(1):126-39.

Nguyen TTU, Kim HW, Kim W. Effects of probiotics, prebiotics and synbiotics on uremic toxins, inflammation and oxidative stress in hemodialysis patients: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2021;10(19):4456.

Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212-22.

Zhu Q, Dai L. Prognostic implications of systemic immune-inflammation index and systemic inflammation response index in hemodialysis patients. BMC Nephrol. 2025;26:322.

Soleimani A, Zarrati Mojarrad M, Bahmani F, Taghizadeh M, Ramezani M, Tajabadi-Ebrahimi M, et al. Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. Kidney Int. 2017;91(2):435-42.

Haghighat N, Mohammadshahi M, Shayanpour S, Haghighizadeh MH. Effects of synbiotics and probiotics supplementation on serum levels of endotoxin, heat shock protein 70 antibodies and inflammatory markers in hemodialysis patients: a randomized double-blinded controlled trial. Probiotics Antimicrob Proteins. 2020;12(1):144-51.

Kooshki A, Tofighiyan T, Miri M. A synbiotic supplement for inflammation and oxidative stress and lipid abnormalities in hemodialysis patients. Hemodial Int. 2019;23(2):254-60.

Mirzaeian S, Saraf-Bank S, Entezari MH, Hekmatdoost A, Feizi A, Atapour A. Effects of synbiotic supplementation on microbiota-derived protein-bound uremic toxins, systemic inflammation and biochemical parameters in patients on hemodialysis: a double-blind, placebo-controlled, randomized clinical trial. Nutrition. 2020;73:110713.

Lim PS, Wang HF, Lee MC, Chiu LS, Wu MY, Chang WC, et al. The efficacy of Lactobacillus-containing probiotic supplementation in hemodialysis patients: a randomized, double-blind, placebo-controlled trial. J Ren Nutr. 2021;31(2):189-98.

Araujo EMR, Meneses GC, Carioca AAF, Martins AMC, Daher EDF, Silva Junior GB. Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial. J Bras Nefrol. 2023;45(2):152-61.

Saad WM, Moheb Y, Wafa E, Elhadedy MA, Sobh MA. Effect of probiotic and synbiotic administration on the nutritional status of hemodialysis patients: a randomized-controlled trial. Int Urol Nephrol. 2026;2:673.

Azad F, Hamidianshirazi M, Mazloomi SM, Shafiee M, Ekramzadeh M. Fortified synbiotic dessert for improving malnutrition in hemodialysis patients: a randomized, double-blind, controlled trial. Food Sci Nutr. 2023;11(12):8082-92.

Shariaty Z, Mahmoodi Shan GR, Farajollahi M, Amerian M, Behnam Pour N. The effects of probiotic supplement on hemoglobin in chronic renal failure patients under hemodialysis: a randomized clinical trial. J Res Med Sci. 2017;22:74.

Haghighat N, Mohammadshahi M, Shayanpour S, Haghighizadeh MH. The effect of synbiotic and probiotic supplementation on mental health parameters in patients undergoing hemodialysis: a double-blind, randomized, placebo-controlled trial. Indian J Nephrol. 2021;31(2):149-56.

Liu C, Yang L, Wei W, Fu P. Efficacy of probiotics/synbiotics supplementation in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Front Nutr. 2024;11:1434613.

Ouellet G, Malhotra R, Penne EL, Usvya L, Levin NW, Kotanko P. Neutrophil-lymphocyte ratio as a novel predictor of survival in chronic hemodialysis patients. Clin Nephrol. 2016;85(4):191-8.

Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55(2):648-58.

Fukasawa H, Ishibuchi K, Kaneko M, Niwa H, Yasuda H, Kumagai H, et al. Red blood cell distribution width is associated with all-cause and cardiovascular mortality in hemodialysis patients. Ther Apher Dial. 2017;21(6):565-71.

Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993;329(14):1001-6.

Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2001;38(6):1251-63.

Rambod M, Bross R, Zitterkoph J, Benner D, Pithia J, Colman S, et al. Association of Malnutrition-Inflammation Score with quality of life and mortality in hemodialysis patients: a 5-year prospective cohort study. Am J Kidney Dis. 2009;53(2):298-309.

Matos CM, Silva LF, Santana LD, Santos LS, Protasio BM, Rocha MT, et al. Handgrip strength at baseline and mortality risk in a cohort of women and men on hemodialysis: a 4-year study. J Ren Nutr. 2014;24(3):157-62.

Mapes DL, Lopes AA, Satayathum S, McCullough KP, Goodkin DA, Locatelli F, et al. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2003;64(1):339-49.

Lopes AA, Bragg-Gresham JL, Satayathum S, McCullough K, Pifer T, Goodkin DA, et al. Health-related quality of life and associated outcomes among hemodialysis patients of different ethnicities in the United States: the Dialysis Outcomes and Practice Patterns Study. Am J Kidney Dis. 2003;41(3):605-15.

Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60(2):129-34.

Bafeta A, Koh M, Riveros C, Ravaud P. Harms reporting in randomized controlled trials of interventions aimed at modifying microbiota: a systematic review. Ann Intern Med. 2018;169(4):240-7.

Rossi M, Johnson DW, Morrison M, Pascoe EM, Coombes JS, Forbes JM, et al. Synbiotics easing renal failure by improving gut microbiology (synergy): a randomized trial. Clin J Am Soc Nephrol. 2016;11(2):223-31.